Eterna Regeneratives Secures Funding For Enamel Repair

Eterna Regeneratives, a King's College London spinout, has secured seed investment led by Hoxton Ventures. The company plans to launch keratin-based enamel repair products by early 2027. This article covers the funding, the team, the science, and what remains unproven.

TL;DR

• Eterna Regeneratives closed a seed round led by Hoxton Ventures, with The Venture Collective also investing.

• The company plans a toothpaste, mouthwash, and professional product by early 2027.

• Lab studies show wool keratin grows enamel-like mineral and resists acid about as well as fluoride.

• Eterna has published no human clinical trials yet, and its bone work remains in animal models.

What Eterna Regeneratives Announced

King's College London announced the investment on September 17, 2026. Hoxton Ventures led the round, and the announcement did not disclose the amount.

The funding covers three goals: faster product development, expanded research, and preparation for market entry. Eterna also moved into new lab space at the Kadans London Innovation Centre in Canary Wharf. The company website lists The Venture Collective alongside Hoxton Ventures as an investor.

Hussein Kanji, founding partner at Hoxton Ventures, described the company as built on "powerful, defensible science." He also pointed to what he called a capital-efficient route to market. That phrase fits the business model. Eterna plans to embed its material into everyday products such as toothpaste and mouthwash.

Who Runs Eterna Regeneratives

Eterna was founded in 2024 as a spinout from King's College London. Its leadership pairs clinical research with consumer health experience, according to the company team page.

Dr. Sherif Elsharkawy serves as chief scientific officer and co-founder. He lectures in prosthodontics at King's College London and consults at Guy's and St Thomas'. His PhD in bioengineering and materials science focused on biomineralization.

Khaled Eissa is chief executive and co-founder. He holds a PhD in sociology from the University of Cambridge. He previously founded an investment vehicle that backed early-stage technology companies.

Carl Dempsey leads the commercial side as chief business officer. He spent 29 years at Johnson & Johnson. His final role there was worldwide vice president, global customer management. Dr. Sara Gamea, the founding study's first author, is now a senior scientist at Eterna. The company lists her as co-inventor of its patented technology.

The Keratin Technology Behind Eterna

Eterna's platform uses keratin extracted from sheep's wool. The company outlines a six-step mechanism on its enamel repair page.

Keratin starts as a soluble protein. On the tooth, it self-assembles into structured templates rich in beta-sheet spherulites. These templates offer nucleation sites for calcium and phosphate from saliva. Apatite nanocrystals then grow from the scaffold into organized, enamel-like mineral.

The founding research appeared in Advanced Healthcare Materials in 2025, with Sara Gamea as first author. The team used water-based keratin films. King's College London named toothpaste and a professional gel as possible delivery formats.

Enamel forms in a similar way during tooth development. Proteins such as amelogenin act as a template and guide crystals into aligned rods. Those enamel-forming cells disappear once a tooth erupts, so lost enamel never grows back. Eterna aims to supply the missing template from outside the body.

What Eterna's Published Studies Show

The company website lists four peer-reviewed papers. All enamel testing so far used extracted teeth or enamel samples in the lab.

The founding study grew an enamel-like layer with much of healthy enamel's hardness and strength. A 2026 pilot study in the Journal of Dentistry tested 44 acid-eroded human enamel samples. A single application of 10% keratin performed about as well as 1,450 ppm sodium fluoride. Both clearly outperformed the untreated control.

A second 2026 study in Frontiers in Dental Medicine compared keratin against fluoride at several concentrations. Keratin preserved enamel surface structure about as well as a 22,600 ppm fluoride group. That concentration matches professional fluoride varnish. Eterna also reports that its mineral layer stayed in place after a controlled toothbrushing test.

Matching fluoride in the lab is a strong early result for a new material. It also means keratin has not yet shown clear superiority over the current standard.

Eterna's Product Pipeline

Eterna plans three enamel products and a separate bone regeneration program.

The enamel line covers a toothpaste, a mouthwash, and a professionally applied product. The 2025 King's College announcement compared the professional format to a gel applied like nail varnish. The company targets consumer availability by early 2027.

The bone program sits at an earlier stage. In April 2026, King's College London reported bone results in animal models. Wool-derived keratin membranes supported guided bone regeneration. The underlying Biomaterials Advances study tested the membranes in rat skull defects. Eterna's bone page describes a membrane that keeps soft tissue out while bone fills the defect. Dental surgeons use collagen and PTFE membranes for the same purpose in guided bone regeneration today.

How Eterna's Approach Compares With Current Options

Eterna enters a field that already has several enamel repair tools. Each targets a different stage of damage, and the evidence behind them varies widely.

Fluoride remains the baseline. It converts surface mineral into fluorapatite, which dissolves less readily in acid. The American Dental Association requires fluoride for its Seal of Acceptance on toothpaste. Readers comparing options can start with the best fluoride toothpaste picks.

Nano-hydroxyapatite sits closest to the Eterna concept. It delivers enamel-like mineral directly to the tooth surface. The guide to enamel and gum repair toothpaste covers current options.

Two professional treatments also target early lesions. Self-assembling peptide P11-4, sold as Curodont, builds a scaffold inside the lesion. The vVardis Curodont review covers its clinical handling. Resin infiltration seals porous enamel without drilling, as the Icon resin infiltration review explains. Eterna shares the scaffold idea with P11-4, though its keratin layer forms on the outer surface.

Open Questions Before Launch

The funding moves Eterna toward market, and several questions remain open. Clinicians and investors will be watching the same ones.

No human clinical trial has been published. A real mouth adds dietary acids, bacterial biofilm, and the salivary pellicle. Each factor could change how the layer forms and how long it lasts.

Delivery is the second unknown. The founding study applied keratin as a film. A toothpaste stays on the teeth for about two minutes before rinsing. Eterna has not published results for its consumer formats.

Pricing and brand partners have not been announced. The company website also notes that its statements reflect research status and are "not clinical claims." That wording is an accurate summary of where the evidence stands.

What Dental Professionals Can Tell Patients

Patients who saw the funding news may ask about Eterna at their next visit. A short, accurate answer helps set expectations.

No Eterna product is on the market as of September 2026. Current advice for enamel protection stays the same. That means fluoride toothpaste twice daily, fewer acidic drinks, and regular checkups. Patients with early white spot lesions can discuss remineralization or infiltration options today.

Clinicians can describe Eterna as a funded company with promising lab data and a 2027 target. Human trial results will show how its products perform in real mouths.

Bottom Line

Eterna Regeneratives now has seed funding, new lab space, and consumer health leadership. Its keratin technology matches fluoride in lab erosion tests and forms enamel-like mineral on extracted teeth.

Clinical proof has not arrived yet, and the bone program remains in animal studies. Human trials and the 2027 launch are the milestones to watch.